S
Songwen Zhou
Researcher at Tongji University
Publications - 36
Citations - 5000
Songwen Zhou is an academic researcher from Tongji University. The author has contributed to research in topics: Lung cancer & Erlotinib. The author has an hindex of 18, co-authored 33 publications receiving 4446 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Jifeng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more
TL;DR: It is suggested that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC, and was associated with more favourable tolerability than standard chemotherapy.
Journal ArticleDOI
Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Ji Feng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jian Wang,Songwen Zhou,Shengxiang Ren,Shaoyong Lu,Lin Zhang,Chengping Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +21 more
TL;DR: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutation-positive advanced non-small-cell lung cancer patients, suggesting that erlotinib should be considered standard first-line treatment of EGfr mutant patients and EGFR -TKI treatment following first- line therapy also brings significant benefits to those patients.
Journal ArticleDOI
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
Bing Li,Shengxiang Ren,Xuefei Li,Yongsheng Wang,David Garfield,Songwen Zhou,Xiaoxia Chen,Chunxia Su,Mo Chen,Peng Kuang,Guanghui Gao,Yayi He,Lihong Fan,Ke Fei,Caicun Zhou,Gerald Schmit-Bindert +15 more
TL;DR: In this article, miR-21 was found to be involved in acquired resistance of EGFR-TKI in NSCLC, which is mediated by down-regulating PTEN and PDCD4 and activating PI3K/Akt pathway.
Journal ArticleDOI
MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
TL;DR: In this article, microRNAs (miRs) were shown to regulate the acquired resistance to gefitinib in HCC827/GR via PTEN/AKT signaling pathway.
Journal ArticleDOI
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
Gongyan Chen,Ji Feng Feng,Caicun Zhou,Yi-Long Wu,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jian Wang,Songwen Zhou,Shengxiang Ren,Shaoyong Lu,Lei Zhang,C.-P. Hu,Chengping Hu,Y. Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yuling Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more
TL;DR: Erlotinib improves QoL compared with standard chemotherapy in the first-line treatment of patients with EGFR mutation-positive advanced NSCLC and updated PFS analyses from this study are described.